产品
编 号：F186434
分子式：C23H27FN4O6S
分子量：506.55
分子式：C23H27FN4O6S
分子量：506.55
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 156547-56-7
产品详情
生物活性：
FSCPX is a potent and selective irreversible antagonist of A1 adenosine receptor (A1AR), with low nanomolar potency for binding to the A1AR. FSCPX could modify the effect of NBTI, a nucleoside transport inhibitor, by reducing the interstitial adenosine level in the guinea pig atrium.
体外研究：
FSCPX irreversibly blocks the binding of [3H]-8-cyclopentyl-1,3dipropylxanthine ([3H]DPCPX), with an IC50 of 11.8±3.2 nM in DDT1 MF2 cells.FSCPX (20 μM; 48 h) attenuates protection from necrosis and apoptosis in A1AR-overexpressing LLC-PK1 cells.FSCPX (2-20 μM; 48 h) reverses the upregulation of HSP27 mRNA and protein in A1AR-overexpressing LLC-PK1 cells without an effect on the mRNA or protein for HSP70.
FSCPX is a potent and selective irreversible antagonist of A1 adenosine receptor (A1AR), with low nanomolar potency for binding to the A1AR. FSCPX could modify the effect of NBTI, a nucleoside transport inhibitor, by reducing the interstitial adenosine level in the guinea pig atrium.
体外研究：
FSCPX irreversibly blocks the binding of [3H]-8-cyclopentyl-1,3dipropylxanthine ([3H]DPCPX), with an IC50 of 11.8±3.2 nM in DDT1 MF2 cells.FSCPX (20 μM; 48 h) attenuates protection from necrosis and apoptosis in A1AR-overexpressing LLC-PK1 cells.FSCPX (2-20 μM; 48 h) reverses the upregulation of HSP27 mRNA and protein in A1AR-overexpressing LLC-PK1 cells without an effect on the mRNA or protein for HSP70.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备